INOVIQ Ltd

DB:EGQ0 Stock Report

Market Cap: €34.8m

INOVIQ Valuation

Is EGQ0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EGQ0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EGQ0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EGQ0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EGQ0?

Key metric: As EGQ0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EGQ0. This is calculated by dividing EGQ0's market cap by their current revenue.
What is EGQ0's PS Ratio?
PS Ratio37.1x
SalesAU$1.56m
Market CapAU$57.99m

Price to Sales Ratio vs Peers

How does EGQ0's PS Ratio compare to its peers?

The above table shows the PS ratio for EGQ0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.4x
V3V VITA 34
0.9x3.1%€71.8m
MAK Maternus-Kliniken
0.3xn/a€29.1m
JTH Gesundheitswelt Chiemgau
0.3xn/a€23.8m
HAEK HAEMATO
0.2xn/a€56.5m
EGQ0 INOVIQ
37.1x70.9%€58.0m

Price-To-Sales vs Peers: EGQ0 is expensive based on its Price-To-Sales Ratio (37.1x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does EGQ0's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.09xn/aUS$4.79m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.39m
No more companies available in this PS range
EGQ0 37.1xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EGQ0 is expensive based on its Price-To-Sales Ratio (37.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is EGQ0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EGQ0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio37.1x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: EGQ0 is expensive based on its Price-To-Sales Ratio (37.1x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 09:17
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

INOVIQ Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris KallosMST Financial Services Pty Limited